Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pruritus refers to the *unpleasant sensation that provokes the desire to scratch the skin*. It is a symptom, not a molecular entity. Pruritus can be caused by a wide range of conditions including dry skin, allergic reactions, skin disorders (e.g., eczema, psoriasis), internal diseases (e.g., liver or kidney disease), certain medications, and sometimes underlying systemic illnesses such as diabetes or cancer[1][3][5][7]. Biologically, pruritus is mediated by the activation of peripheral sensory nerve fibers, which transmit itch signals to the central nervous system through complex neural pathways, and is amplified by mediators such as **histamine**, **cytokines (e.g., IL-31)**, **proteinase-activated receptors (PAR2)**, **TRP (transient receptor potential) channels**, and **opioid receptors**[2][4][6][7]. Therapies for pruritus are designed to address underlying causes or modulate signaling mechanisms but do not target "pruritus" directly as a molecule or receptor. Key points: - **Pruritus** is *not* a specific molecule, protein, or receptor and therefore cannot be directly targeted like "histamine receptor" or "IL-31 receptor," though these and other molecules are implicated in its mechanisms[2][4][6]. - Treatments for pruritus often involve antihistamines, corticosteroids, emollients, drugs targeting IL-31/IL-31Rα axis, or modulators of opioid or neuropeptide signaling[4][7]. For structured target data, "Pruritus" should be considered an *incorrect* entry if used as a drug target or receptor. If the intention is to describe molecular targets involved in pruritus, examples include: - **Histamine H1 receptor (H1R)** - **Interleukin-31 receptor alpha (IL-31Rα)** - **Proteinase-activated receptor 2 (PAR2)** - **Transient receptor potential cation channel subfamily V member 1 (TRPV1)** - **Gastrin-releasing peptide receptor (GRPR)** - **Opioid receptors (mu, kappa)** These represent canonical molecule/receptor targets *involved in pruritus*, but "Pruritus" itself should not be used as a target name[2][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pruritus.